Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier
WebMD

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine
WebMD

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion
    WebMD

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community
    WebMD

    Community

    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Schizophrenia Health Center

Font Size
A
A
A

FDA OKs Abilify for Teen Schizophrenia

Abilify Now Second Schizophrenia Drug Approved for Teens
By
WebMD Health News
Reviewed by Louise Chang, MD

Nov. 6, 2007 -- The FDA has approved the atypical antipsychotic drug Abilify for the treatment of schizophrenia in teens aged 13-17.

Atypical antipsychotic drugs are a newer type of antipsychotic drugs.

It's only the second drug specifically approved to treat schizophrenia in teens. Last August, the FDA approved Risperdal for the treatment of schizophrenia in adolescents aged 13-17.

Abilify was approved for adults with schizophrenia in November 2002. The drug is also used to treat bipolar disorder in adults. Through June 2007, Otsuka Pharmaceutical Co. Ltd. and Bristol-Myers Squibb report that U.S. doctors have written more than 12.5 million prescriptions for the drug.

The approval for teens is based on a clinical trial in which more than 300 teens undergoing an acute schizophrenia episode received one of two doses of Abilify (10 milligrams/day or 30 milligrams/day) or an inactive placebo. Both doses of Abilify improved schizophrenia symptoms better than the placebo.

Side effects seen in the study included extrapyramidal disorder (physical symptoms such as involuntary muscle movements, abnormal posture, and slurred speech), sleepiness, and tremor. These side effects were more common in teens taking higher doses of the drug.

However, side effects led to treatment discontinuation in only 5% of Abilify patients (and in 2% of placebo patients).

Weight gain is a typical side effect of older antipsychotic drugs, but it is far less common with atypical antipsychotics, including Abilify. One in 20 patients treated with Abilify had a 7% or greater weight gain.

Today on WebMD

69X75_Depression.jpg
Article
Mental Health Psychotic Disorders
Article
 
Schizophrenia Medications
Article
bored man resting chin on hands
Article
 
vincent van gogh
Article
paranoia
Slideshow
 
Schizophrenia What Increases Your Risk
Article
mother and daughter
Article
 
boy hiding under blanket
Article
male patient with doctor
Article
 
romantic couple
Article
businesswoman working at desk at night
Article